Substrate Analogue Targeting Glutamate Racemase (MurI) Alters Cellular Morphogenesis And Inhibits Biofilm Formation In Streptococcus Mutans | 64992
Journal of Oral Hygiene & Health
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
D-Glutamate (D-Glu) is an essential biosynthetic building block of the peptidoglycans that encapsulate the bacterial cell wall.
Glutamate racemase (MurI) catalyses the reversible formation of D-glutamate from L-glutamate and, hence, the enzyme is a
potential therapeutic target. The current study was designed to identify novel molecules that target glutamate racemase, thereby
mitigating S. mutans cariogenic capacities, inhibiting biofilm formation and having the potential to prevent dental caries. High
throughput screening of approximately 250 commercially available compounds against the recombinant S. mutans glutamate
racemase resulted in the identification of a substrate-product analogue, D-glutamine, as a modest competitive inhibitor of glutamate
racemase. In vitro assays, the addition of D-glutamine blocked the D-Glu metabolic way in S. mutans, leading to malformations in
bacterial cell wall, inhibition of biofilm formation, and reductions in extracellular polysaccharide (EPS) synthesis without necessarily
killing this bacterium directly. The exogenous addition of D-Glu could partially reverse the inhibitory effect of D-glutamine. In
conclusion, these findings suggest that the substrate analogue of glutamate racemase represents a promising anti-cariogenic agent in
that it suppresses virulence properties of S. mutans by affecting D-Glu metabolism.